C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/62 (2006.01) A61K 39/395 (2006.01) A61K 47/48 (2006.01) C07K 14/21 (2006.01) C07K 16/18 (2006.01) C07K 16/30 (2006.01) C07K 16/34 (2006.01) C07K 16/46 (2006.01) C07K 19/00 (2006.01) C12N 15/13 (2006.01) C12N 15/31 (2006.01) G01N 33/574 (2006.01) G01N 33/577 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2203236
This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis Y-related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv (ScFv) regions of the monoclonal antibodies B1, B3, and B5, humanized single chain Fv regions of B1, B3, and B5, and fusion proteins comprising these scFv regions. The invention also provides for a number of stabilizing mutations of the Lewis Y-binding monoclonal antibody B3. In addition, the invention provides for methods of detecting cells bearing a Lewis Y antigen in a patient and for methods of killing or inhibiting the growth of cells bearing a Lewis Y antigen in a patient. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the VH region that involves mutating position 95 to a serine.
La présente invention porte sur des anticorps à chaîne unique recombinants capables de se lier spécifiquement à un antigène glucidique de type Lewis Y et sur des protéines de fusion comprenant ces anticorps. Plus particulièrement, l'invention a trait à des régions Fv (ScFv) à chaîne unique des anticorps monoclonaux B1, B3 et B5, à des régions Fv à chaîne unique humanisées de ces anticorps et à des protéines de fusion comprenant ces régions scFv. L'invention a trait également à un certain nombre de mutations stabilisatrices de l'anticorps B3 monoclonal liant un antigène Lewis B. En outre, l'invention a trait à des méthodes de détection des cellules renfermant un antigène de type Lewis Y chez un patient et à des méthodes permettant de tuer ces cellules ou d'inhiber leur croissance. L'invention porte également sur une méthode d'amélioration de l'affinité des anticorps dépourvus d'une sérine en position 95 de la région VH, qui consiste à placer une sérine en position 95 par mutation.
Benhar Itai
Brinkmann Ulrich
Fitzgerald David
Jung Sun-Hee
Lee Byungkook
Department Of Health And Human Services The Government Of The United States Of America Represented By Th
Fetherstonhaugh & Co.
The Government Of The United States Of America As Represented By The Se Cretary Of The Department Of Health And
LandOfFree
Tumor-specific antibody fragments, fusion proteins, and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor-specific antibody fragments, fusion proteins, and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor-specific antibody fragments, fusion proteins, and uses... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1595156